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Pharmaceuticals have been considered ‘contaminants of emerging concern’ for more than 20 years. In
that time, many laboratory studies have sought to identify hazard and assess risk in the aquatic envi-
ronment, whilst ﬁeld studies have searched for targeted candidates and occurrence trends using
advanced analytical techniques. However, a lack of a systematic approach to the detection and quanti-
ﬁcation of pharmaceuticals has provided a fragmented literature of serendipitous approaches. Evaluation
of the extent of the risk for the plethora of human and veterinary pharmaceuticals available requires the
reliable measurement of trace levels of contaminants across different environmental compartments
(water, sediment, biota - of which biota has been largely neglected). The focus on pharmaceutical con-
centrations in surface waters and other exposure media have therefore limited both the characterisation
of the exposome in aquatic wildlife and the understanding of cause and effect relationships. Here, we
compile the current analytical approaches and available occurrence and accumulation data in biota to
review the current state of research in the ﬁeld. Our analysis provides evidence in support of the
‘Matthew Effect’ and raises critical questions about the use of targeted analyte lists for biomonitoring. We
provide six recommendations to stimulate and improve future research avenues.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Pharmaceuticals as a cause for concern in the aquatic
environment
Chemical contaminants entering the environment are a
consistent cause for concern. In particular, pharmaceutical and
personal care products (PPCPs) have been identiﬁed as emerging
contaminants (Daughton and Ternes, 1999; Ellis, 2006), i.e. com-
pounds which are not routinely monitored and are suspected to
cause adverse effects in the environment. In 2015, at the Interna-
tional Conference on Chemicals Management (ICCM), thee by Klaus Kummerer.
l Sciences Division, Faculty of
Stamford Street, London, SE1
er).
r Ltd. This is an open access articlepharmaceutical industry and non-governmental bodies agreed that
the environment now requires protection from “pharmaceutical
pollution” (Time to get clean. Nature, 2015). The combination of
total compounds exposed to, and their effects on, an organism over
an entire life cycle is termed the ‘exposome’ (Rappaport, 2011;
Escher and Hermens, 2004). Global occurrence and fate in abiotic
aqueous (Balakrishna et al., 2017; Bu et al., 2013; Heberer, 2002)
and solid matrices (Díaz-Cruz et al., 2003; Halling-Sørensen et al.,
1998; Pan et al., 2009; Tadeo et al., 2012) have formed the focus
of several in-depth reviews. In the context of the exposome -
especially pharmaceutical residues - it is arguably the internalised
compound concentrations that will determine biological effects in
an organism. To date, biomonitoring of pharmaceuticals in aquatic
biota (as potentially the most at risk group) have not been reviewed
in great depth as studies have only relatively recently begun to
emerge more frequently in the literature. However, we direct the
reader to earlier literature from 2011, that covers a wide range of
contaminants in aquatic wildlife including the very ﬁrst studiesunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Meador, 2011).
The EU Water Framework Directive has included pharmaceuti-
cals on a dynamic ‘watch-list’ based on potential for adverse effects
in the aquatic environment. This list includes insecticides, herbi-
cides, a sunscreen, several antibiotics, some natural hormones and
two pharmaceuticals (17-alpha-Ethinylestradiol (EE2) from the
birth control pill and diclofenac, a non-steroidal inﬂammatory
drug) under the Environmental Quality Standards Directive and are
subject to European monitoring (Carvalhoet al, 2015). The
Convention for the Protection of the Marine Environment of the
North-East Atlantic (OSPAR) was the ﬁrst body to formally recog-
nise pharmaceutical contamination, where the compound clotri-
mazole was included on their priority action list (OSPAR, 2002).
OSPAR now lists 28 substances or groups of substances, with a
further 264 compounds (including 25 pharmaceuticals) as con-
taminants of possible concern under four separate categories
(OSPAR). Several non-regulatory groups, such as the Network of
reference laboratories, research centres and related organisations
for monitoring of emerging environmental substances (NORMAN),
share knowledge on environmental contaminants gathered from
monitoring campaigns and aim to harmonise analytical approaches
for contaminant identiﬁcation and determination in a range of
environmental compartments (Brack et al., 2012). Other groups
include those such as the United Nations Educational, Scientiﬁc,
and Cultural Organization (UNESCO) which have recently released
a series on ‘emerging pollutants in water’ (UNESCO and HELCOM,
2017). Whilst, the collation and dissemination of information
from these groups is valuable, it is also essential that reported in-
formation is consistent and accurate otherwise it can lead to
reduced data value. Therefore, it may be prudent to standardise
units when reporting occurrence data (e.g. mg L1) to avoid this type
of error. As observed in other ﬁelds, reporting to accepted quality
standards in research articles is critical if they are used to help
inform policy, scientiﬁc practice and knowledge (Munafo et al.,
2017). However, research articles can omit critical information
relevant to the study and this potentially decrease their value.
Appropriate chemical analysis method validation guidelines should
be used, ideally integrated within the wider umbrella of acceptable
reporting guidelines, and this would help ensure the reliability of
any reported contaminant concentrations in biota. A range of
guidelines are available that have been developed to improve
reporting standards across health research (Simera et al., 2010) and
this should ideally be no different for ecotoxicology. For example,
guidelines such as Animals in Research: Reporting In Vivo Experi-
ments (ARRIVE) (Kilkenny et al., 2010) could be adapted to improve
the reporting standards for monitoring campaigns and effect-based
studies (especially those using bespoke behavioural endpoints).
However, guidelines for both method validation and reporting
standards still require consensus within the scientiﬁc community
in this particular ﬁeld.
Pharmaceutical concentrations in environmental waters are
generally considered non-toxic to humans directly (ng-mg L1), but
this may not be the case for wildlife. Unlike other traditional
persistent organic pollutants, PPCPs are not so easily classiﬁed as
they are not always persistent. They are, however, pseudo-
persistent due to continual inﬂux to the environment from
several sources, including waste water treatment plants (WWTPs),
manufacturing, agriculture and aquaculture, amongst other routes
(Boxall et al., 2012). Furthermore, pharmaceuticals are generally
designed not to be bioaccumulative (Lipinski et al., 1997), as
demonstrated during in vivo laboratory exposures (Miller et al,
2016, 2017; Meredith-Williams et al., 2012; Nichols et al., 2015;
Nallani et al., 2011). Effects are often studied and observed at non-
environmentally relevant concentrations of single compounds (i.e.acute toxicity) under deﬁned laboratory conditions (Carlsson et al.,
2006). Any effects observed are generally not explicitly linked to
the cause (i.e. the internalised drug is not determined) (Rand-
Weaver et al., 2013). Pharmaceutical residues are rarely moni-
tored within wild biota, leading to a knowledge gap in the extent
and route of exposure these organisms encounter over their life-
time within their respective habitats. Thus, measurement of phar-
maceutical tissue concentrations in aquatic wildlife is increasingly
important. The challenges in understanding potential environ-
mental risks are exacerbated by a large disparity between labora-
tory and the ﬁeld-derived bioconcentration data. Surface water
drug concentration measurements are a useful alternative, and
have been the focus to date, but represent only one single
compartment. For example, partitioning to sediments also needs to
be considered, especially for benthic-dwelling organisms (Gilroy
et al., 2012). Signiﬁcant spatial and temporal ﬂuctuations also
exist (Miller et al., 2015; Luo et al., 2014). For pharmaceuticals,
further complexity is added by their ionisation state in comparison
to typical non-polar compounds, and this is important because it
makes comparisons difﬁcult across scenarios where water chem-
istry can impact ionisation and therefore uptake into biota
(Karlsson et al., 2017).
Pharmaceuticals are often designed to cross biological mem-
branes and therefore rate of uptake and internal concentrations are
critically important. Therefore, to fully understand the potential for
pharmaceuticals to cause harm in the aquatic environment, it is
essential to assess wider occurrence in biota (including ﬁsh, in-
vertebrates, plants and algae). The limited number of reports de-
tailing occurrence in biota is potentially caused by two factors. The
ﬁrst of these is biological variation (there are estimated to be
~31,000 ﬁsh species and ~176,000 aquatic invertebrates described
to date). The second is the analytical capabilities required for broad
scope, multi-residue determination of thousands of human and
veterinary pharmaceuticals and their metabolites in so many
complex matrices at very high sensitivity.
The aim of this work is to review the occurrence of pharma-
ceutical residues in aquatic fauna. As part of this, a critical discus-
sion will be presented focussing on (a) the range and reliability of
analytical approaches for trace pharmaceutical and metabolite
determination in aquatic fauna; (b) the reported occurrence of
pharmaceuticals across a range of species, including ﬁsh and in-
vertebrates, up to 2016; and (c) the bioaccumulation potential of
pharmaceuticals and comparisons of ﬁeld- and laboratory-based
measurements. The use and collation of biomonitoring data to
characterise pharmaceutical contamination is critical to under-
standing the extent of exposure and potential impact on aquatic
fauna.
2. Systematic literature searching and statistical tests
A systematic search of published reports in the literature was
performed using Scopus® (Elsevier, Netherlands). Several keywords
were included to identify published works for pharmaceutical
occurrence in ﬁsh and invertebrates. These included “occurrence”,
“PPCPs” or “pharmaceuticals”, and “ﬁsh” or “invertebrates”. The
terms were searched across document titles, types, abstracts and
keyword lists across all years up to 2016. The same keywords were
also included in searches using Google Scholar up to 2016, to
improve coverage of the available literature. Using this structured
search strategy and to the best of our ability, all papers on phar-
maceutical occurrence in aquatic fauna (ﬁsh or invertebrates) have
been included, see Supplementary Information (SI) for full occur-
rence data tables. All statistical tests were performed in Minitab 18
(Minitab Inc., US) or Sigma Plot (Systat Software Inc., US) with a
signiﬁcance level set to alpha¼ 0.05.
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and invertebrates
The typical workﬂow for determination of pharmaceuticals in
abiotic or biota samples encompasses four overarching steps:
sample preparation, conﬁrmatory-level instrumental analysis data
processing/interpretation and application (Fig. 1). Sample prepa-
ration can be further divided into sample collection/pre-processing,
analyte extraction and clean up/pre-concentration. Analyte physi-
cochemical properties have often governed the development and
performance of robust analytical methods. Generally, studies
focussing on biomonitoring cover small groups of compounds to
maximise the quality of analytical determinations at high sensi-
tivity. For analysis, either liquid (LC) or gas chromatography (GC)
coupled to mass spectrometry (MS) are normally applied, due to
their sensitivity and suitability for qualitative and quantitative
analysis. For broad-scope quantitative screening, compound di-
versity can make analytical performance more variable across a
wider analyte set.
Analytical methods vary for analysis of different biotic matrices,
but mainly in their sample pre-treatment steps (Table S2 & S3) and
special focus will be placed here in this review. It is important for
broad-scope extraction methods applied to several thousandFig. 1. Overview of the analytical workﬂow for determination of exogenous or endogenous c
can terminate after the application stage.potentially relevant compounds, that a suitable extraction method
is used to capture as many of these as possible, but while also
limiting matrix interference. For pharmaceuticals by design, they
generally follow Lipinski's ‘Rule of 5’ (Lipinski et al., 1997) deﬁned
as (a) small molecules (<500 Da, with the obvious exception of
biopharmaceuticals, which for the purposes of this review, are
excluded), (b) display octanol-water partition coefﬁcients (logP)< 5
(in contrast to persistent organic pollutants, they are therefore of
moderate polarity), and (c) have less than ﬁve proton donors and
acceptors (and are therefore acidic, basic, zwitterionic and neutral
molecules at physiological pH). These rules allow pharmaceuticals
to partition better acrossmembranes and are easily absorbed by the
body (and by biota) as a result. As many are small molecules, they
can generally be extracted from matrix by size relatively easily.
Secondly, on an intra-molecular level they often contain either ar-
omatic functionalities (which can be extracted via induced-dipoles
or via pi-pi interactions), polar groups (e.g. amides, ketones, hy-
droxyl groups etc. which can be extracted via dipole-dipole in-
teractions and/or H-bonding) and/or are often ionisable
(extractable via ion exchange mechanisms). Pharmaceutical me-
tabolites are usually more polar and exist either as transformation
products or as conjugated substances. However, this is sometimes
the opposite for pro-drugs, which may become less polar onceompounds from biological samples. The hyphenated arrow indicates that the work-ﬂow
Fig. 2. Comparison of reported recoveries for pharmaceuticals using different sample
preparation methods determined in (a) ﬁsh and (b) invertebrates. Extraction indicates
the use of liquid extraction only followed by either centrifugation and/or ﬁltration.
Boxes represent the 25th, median and 75th percentile, whiskers represent 10 and 90th
percentile and dots indicate outliers. Parentheses indicate the number of studies for
each method.
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compounds (precursors and biotransformation products) in a sin-
gle assay are likely to vary substantially, as the ability to extract and
detect many of them simultaneously is extremely challenging. As
such, reliable measurement at the ng-mg g1 level is mainly
dependent on analyte recovery and matrix interference (both
during extraction and instrumental analysis). In particular, sample
size, matrix constituents/type, solvent chemistry (including pH,
volume, salt/buffer/ligand concentration etc.), analyte chemistry,
and operating conditions (temperature, agitation etc.) will affect
the performance of any of the extraction techniques outlined above.
3.1. Biological ﬂuids
In much the same way as for human body ﬂuid matrices, liquid
matrices from aquatic biota (such as bile or plasma) are commonly
extracted via ﬁltration, protein precipitation, centrifugation, fol-
lowed by matrix clean up/analyte concentration. Solid phase
extraction (SPE) has been used extensively for the latter and has
enabled better selectivity and sensitivity for environmentally
relevant pharmaceutical residue concentrations. Mixed-mode sor-
bents containing vinylbenzene co-polymerised or functionalised
with polar moieties (e.g. N-vinylpyrrolidone, hydroxyl or cyano
groups) or ion exchangers have dominated this ﬁeld because they
are more broadly applicable to moderate polarity and/or ionic
compounds like many pharmaceuticals. A key drawback to this
technique is that one sorbent may not provide sufﬁcient recovery of
all relevant compounds (for example very polar, conjugated me-
tabolites and/or transformation products). As such, evenwith state-
of-the-art analytical instruments, some compounds remain unde-
tectable in extracts. However, with rapid advancements in instru-
mental sensitivity and chromatography techniques, direct analysis
is becoming possible which may reduce this need for analyte
concentrationwith SPE (Bayen et al., 2015; Campbell et al., 2011; Yu
et al., 2012; Vergeynst et al., 2014). Focus may shift to using SPE
only for matrix removal, if at all.
3.2. Solid and semi-solid matrices
Clear mechanisms that govern occurrence in biota are lacking
and this makes successful analyte pre-selection for method
development much more difﬁcult. The most common approach for
sensitive analysis of semi-solid biotic matrices is the employment
of two pre-treatment steps: (a) extraction of analytes from the solid
matrix and (b) further matrix clean-up and analyte concentration
to enable highly sensitive determination. Interestingly and impor-
tantly, while some niche applications may require it, increasing the
sample preparation complexity for solids using several steps does
not necessarily demonstrate improved method performance for
small sets of individual compounds and where sensitivity may not
be a signiﬁcant hindrance. For example, Subedi et al. (2012) used a
simple liquid extraction (LE) followed by evaporation of the extract
and reconstitution in starting mobile phase for 17 pharmaceuticals
and achieved recoveries ranging from 80 to 98%, with good preci-
sion. Several other works presented in Table S2-S3 have also simply
used LE followed by centrifugation and/or syringe ﬁltering have
achieved similar recoveries across ﬁsh matrices (median recov-
ery¼ 88%) (Subedi et al., 2012; Du et al., 2012; Ramirez et al, 2007,
2009; Schultz et al., 2010), compared to those employing increas-
ingly complex sample preparations (Fig. 2(a)), such as LE and SPE
(median recovery¼ 87%) (Brooks et al., 2005; Brown et al., 2007;
Schuetze et al., 2008; Yu and Wu, 2015; Zhao et al., 2015), micro-
wave assisted extraction (median recovery¼ 87%) (Fernandez-
Torres et al., 2011), pressurised liquid extraction (PLE) followed by
gel permeation chromatography (GPC) (median recovery¼ 52%)(Valdes et al., 2016). However, PLE and SPE together achieved the
best recoveries with a median of 95% (Chu and Metcalfe, 2007; Li
et al., 2012; Xie et al., 2015). PLE has also been used regularly on
several abiotic samples (Jacobsen et al., 2004; Herrero et al., 2013;
Krogh et al., 2008; Rodil and Moeder, 2008). In addition, PLE has
advantages in that it is automated, can minimise thermal trans-
formation of some labile pharmaceuticals, lower the solvent vis-
cosity, improve analyte solubility, increase disruption of matrix-
analyte interactions and increase diffusion rates enabling better
extraction efﬁciency and recovery in a minimised extract volume
(Barron et al., 2008). Only a single method used GPC together with
SPE, where recovery was determined for a total of 13 pharmaceu-
ticals (Tanoue et al., 2014). Only one study used solid phase micro
extraction (SPME), but it showed the lowest recoveries from ﬁsh
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A newer, potentially more streamlined, broadly applicable
extraction approach was introduced in 2003 termed Quick, Easy,
Cheap, Effective, Rugged and Safe (QuEChERS) (Anastassiades et al.,
2003), which has been widely adopted for pesticide residues and,
more recently, pharmaceuticals and their metabolites in food
(Berendsen et al., 2013; Lopes et al., 2012; Wiest et al., 2011) and
environmental biota (Wiest et al., 2011; Daniele et al., 2016; Baduel
et al., 2015). A set ‘cocktails’ of solvents, salts, ligands and buffers
are added to an extraction mixture to broadly extract organic res-
idues from (semi-) solids. For quantitation, precision can vary on a
compound by compound basis, but it is very suited to broad-scope
screening of a wider range of low-high polarity components. In
general, salt choice and its inﬂuence on recovery tends to be
compound and matrix dependent and this is mainly governed by
solubility of each component in high/low ionic strength solutions.
For example, atenolol showed MS signal enhancement in extracts
of one species and suppression in another, using the same salts
(Berlioz-Barbier et al., 2014). The addition of chelating ligands such
as ethylenediaminetetraacetic acid (EDTA) can also improve
extraction efﬁciency of some compounds which readily form
complexes with matrices containing metals (Serra-Compte et al.,
2017; Dasenaki and Thomaidis, 2015). Therefore, analytical
methods that have been developed using one matrix may not show
the same performance for another and methods need to be
assessed carefully before application. For added speciﬁcity and to
improve quantitative performance, QuEChERS is often combined
with either SPE or dispersive SPE (dSPE) for matrix removal (Wiest
et al., 2011; Cerqueira et al., 2014; De Carlo et al., 2015; Peysson and
Vulliet, 2013; Huerta et al., 2013). Huerta et al. (2015) compared
three sorbents for removal of invertebrate matrix and showed that
a protein/phospholipid selective sorbent (Waters Ostro™) showed
the best clean up efﬁciencies followed by a divinylbenzene-N-
vinylpyrrolidone copolymer (Oasis HLB™) followed by magnesium
silicate (Florisil®) for analyte recovery. Berlioz-Barbier et al. (2014)
showed that use of primary-secondary amine (PSA) or PSA/C18 as
dSPE sorbents signiﬁcantly reduced analyte recovery for 28 out of
35 emerging contaminants (PPCPs, alkylphenols and plasticisers).
Thus, puriﬁcation was achieved with liquid-liquid extraction (LLE)
using hexane as an alternative. In another study, a comparison of
PLE, QuEChERS or ultrasonic extraction showed that overall PLE
was superior to the other extraction techniques (Huerta et al.,
2013). Furthermore, GPC and two types of SPE (Oasis HLB™ and
Florisil®) were compared, with GPC showing greater performance
in terms of recovery.
4. Matrix effects and analytical method validation
Overall, it is important to note that whilst one methodmay offer
excellent performance for a single matrix, it might not perform as
well for other compounds, or in other matrices, biological material,
or species. A systematic approach to optimising workﬂows incor-
porating different extraction and clean-up workﬂows is critical,
especially for pharmaceutical residue methods that require very
high sensitivity across matrices. For example, fewer sample prep-
aration approaches have been successfully optimised for pharma-
ceuticals in invertebrates when compared to ﬁsh. One observation
is that the variance in recovery from invertebrates has generally
been much greater for methods involving extraction followed by
centrifugation, extraction followed by SPE and PLE and SPE
(Fig. 2(b)). This can be partially explained by the use of smaller
sample sizes of some invertebrates. In contrast to ﬁsh, analyses of
invertebrate ﬂuids such as haemolymph have only been reported
for those dosed at high pharmaceutical concentrations (Gomez-
Jimenez et al., 2008). As such for invertebrates, the most practicalapproach has been via whole-animal analysis. Inostroza et al.
(2016) observed that an increasing sample size of Gammarus
pulex (0.3e3 g) led to greater matrix effects and lower recoveries.
However, no changes were observed above speciﬁc sample mass.
We observed that scaling down the extraction procedure for
G. pulex, including sample sizes from 100mg to 50mg, showed no
statistically signiﬁcant difference in mean recovery for ten selected
pharmaceuticals (Miller et al., 2017). However, the precision
(repeatability) of the method was signiﬁcantly affected at smaller
mass including added variability in matrix effects. Therefore, for
small organisms there seems to be a critical and complex trade-off
between sample size, recovery, matrix effects and precision in or-
der to achieve optimised method sensitivity.
Several authors have (Ramirez et al., 2007; Berlioz-Barbier et al.,
2014; Huerta et al., 2013) shown that both MS-related matrix ef-
fects and analyte recovery can depend on the extraction solvent
used, where moderate polarity solvents enable better recovery and
lower matrix effects. Virtually all analytical methods in ﬁsh and
invertebrates either use methanol or acetonitrile as the organic
extraction solvent (See SI, Table S2 & S3). One advantage of these
moderately polar solvents is that lipids and proteins generally have
low solubility in them and can therefore often be precipitated or
partitioned away from the analytes of interest. For example, in ﬁsh,
Huerta et al. (2013) found that lipid content caused MS signal
suppression and enhancement. The highest signal suppression was
found for ﬁsh livers which corresponded to the highest lipid con-
tent (48%), while whole ﬁsh homogenates had lower lipid content
(15%). High signal suppression was also observed in a study across
three marine mussel species where matrix effects were most sig-
niﬁcant forMytilus galloprovincialis (lipid content 8.8%), in contrast
to Chamelea gallina and Crassostrea gigas (lipid content 4.8% and
2.1%, respectively) (Alvarez-Mu~noz et al., 2015). Matrix effects in
relation to lipids have been well studied and have been noted to
cause suppression or enhancement of the MS signal (Trufelli et al.,
2011; Taylor, 2005).
In general, the mechanisms of MS-related effects are not yet
fully understood, but are postulated to be related to several factors
including (a) variable droplet formation efﬁciency and stability, (b)
the limited numbers of excess charges and competition for space on
the droplet surface, and (c) other physicochemical properties of the
analyte, matrix and internal standard which may affect the ion-
isation process (e.g. polarity) (King et al., 2000; Bonﬁglio et al.,
1999; Matuszewski et al., 2003). In some cases, dilution can over-
come matrix effects and even increase the sensitivity of an assay.
Whilst focussing on pesticides in plants, Stahnke et al. for example,
showed that dilution of extracts reduced ion suppression to 20%
using a set of 156 analytes (Stahnke et al., 2012). However, given
that matrix effects will still likely occur in most methods to some
degree, the most reliable means to quantify pharmaceuticals using
liquid chromatography-mass spectrometry (LC-MS) assays is to use
stable isotope-labelled internal standards (SIL-IS) bearing 13C or
deuterium atoms. Addition of SIL-IS(s) can improve linearity, ac-
curacy and precision of an analytical method (Miller et al., 2017; Du
et al., 2012; Benijts et al., 2004; Hartmann et al., 2007). Further-
more, whilst the SIL-IS can account for matrix effects on its unla-
belled analogue, it may not do so for chemically different analytes
and/or those that are chromatographically resolved (Huerta et al.,
2013). Matrix variability can also affect accuracy of quantiﬁcation
(Wang et al., 2007; Jemal et al., 2003). The cost and availability of
SIL-IS is also a limiting factor, especially for multi-residue analytical
monitoring of metabolites/transformation products of interest in
biota. Where SIL-IS are not used, then external matrix-matched
calibration curves or standard addition calibration can be used.
For the former, contamination with target analytes in the samples
must be determined beforehand. For the latter, it is very time-
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still may suffer from inhomogeneity in small solid sub-samples as
well as variation of the native concentrations in collected wild or-
ganisms (i.e. background contamination).
Interestingly, of all the methods used to determine the occur-
rence of pharmaceuticals in aquatic environments, one study was
found to follow method validation guidelines by the International
Council for Harmonisation of Technical Requirements for Regis-
tration of Pharmaceuticals for Human Use (ICH) (Berlioz-Barbier
et al., 2014). Many research works report “method performance”
as a preliminary assessment of a freshly developed analytical
method. Acceptance criteria are decided ultimately by the author
which may only in part be based on recognised guidelines. (Miller
et al., 2015; Du et al., 2012; Huerta et al, 2013, 2015; Alvarez-Mu~noz
et al., 2015). This is in stark contrast to other sectors where
analytical workﬂows abide by very strict quality standards
(Chandran and Singh, 2007). As environmental samples are often
complex and vary between/within species, and even within bio-
logical compartments, recognised abiotic sample analysis valida-
tion guidelines may not yet be comprehensive enough to allow
biomonitoring to be performed routinely. However, method vali-
dation guidelines used by the food science sector could be adopted
herewhere, for example, the EU already has regulations concerning
method validation in foodstuffs for consumer safety (EC and
Commission Decision, 2002) and has been regulated since 1990
(EC, 1990).
5. Characterising the exposome with chromatography and
high resolution accurate mass spectrometry (HRMS)
Compound mass analysis for biota samples has generally been
performed with either triple quadrupole linear ion traps (QTrap) or
triple quadrupoles given their selectivity, reproducibility and
sensitivity in targeted multi-residue methods. Critical reviews of
targeted quantitative analysis of pharmaceutical residues in such a
complex array of different environmental/biological matrices have
been reported in depth previously (Hernandez et al., 2016). The
focus here is more on methods that are applicable to even broader
coverage of the exposome and the pharmaceutically-related frac-
tion in particular. The advent of LC or GC coupled to high resolution
mass spectrometry (HRMS) has made a signiﬁcant impact in terms
of more comprehensive characterisation of the exposome. Modern
HRMS instruments include time-of-ﬂight and Orbitrap mass ana-
lysers. The merits of each analyser type have also been reviewed
extensively and is not the focus here (Nielen et al., 2007; Rousu
et al., 2010; Eichhorn et al., 2012). However, the vast improve-
ment in instrument mass accuracy and resolution has meant that
shortlisting of suspect candidates for a given m/z is much more
rapid and has signiﬁcantly advanced the identiﬁcation of new or
emerging contaminants in the environment (Krauss et al., 2010).
Early stages of development of targeted methods may be open
to analyte pre-selection bias where targets are chosen based on
previously published investigations, leading to what is known as
the ‘Matthew Effect’ (Daughton, 2014). Full scan HRMS however,
enables a more comprehensive qualitative assessment under-
pinned by actual rather than presumed occurrence in biota. Broadly
applicable methods can be developed covering many compounds
having much wider chemical diversity. That said, previous occur-
rence data can also direct the post-hoc analysis of accrued data, but
it does not preclude retrospective interpretation of additional data
where needed.
To aid identiﬁcation of non-target features, quantitative
structure-retention relationship (QSRR) based tools have been
developed for reliable in silico predictions for gradient LC retention
time (Miller et al., 2013; Bade et al., 2015; Munro et al., 2015;Aalizadeh et al., 2016), even across different analytical systems
(Barron and McEneff, 2016; Stanstrup et al., 2015). Such computa-
tional tools can add further assurance in feature annotation to help
direct standard acquisition for unambiguous identiﬁcation. For
solid samples, the characterisation of the main biotransformation
products of the antidepressant citalopram in sewage sludge were
conﬁrmed by incorporating this in silico prediction approach
(Beretsou et al., 2016).
The main limitation of current LC-HRMS-based methods is the
degree of coverage of the chromatographic separation space. That
is, most occurrence data for emerging contaminants derive from
separations performed using reversed-phase liquid chromatog-
raphy (RPLC), which favours mid-non-polarity analytes. It fails for
separation of very polar or inorganic compounds, although
methods using ion chromatography (IC) coupled to electrospray
ionisation (ESI)- or inductively coupled plasma (ICP)-MS (or MS/
MS) analysers also exist (Barron and Gilchrist, 2014; Yuan et al.,
2004). IC-HRMS have emerged for small organic and inorganic
ions which are normally not retained well on RPLC stationary
phases (Kohlmeyer et al., 2003). Furthermore, retention mecha-
nisms in IC have been characterised to the point where in silico
QSRR predictive tools can be used for tentative identiﬁcation with
excellent accuracy (Zakaria et al, 2009, 2010). However, to our
knowledge IC-HRMS methods have not yet been widely applied to
the analysis of biota, perhaps largely due to the rise in popularity of
hydrophilic interaction liquid chromatography (HILIC) separation.
HILIC is an adaptation of normal phase chromatography which can
separate organic, inorganic compounds and ionised compounds
with different selectivity to RPLC and IC. Prediction of HILIC
retention times has recently emerged using machine learning
(Taraji et al, 2017a, 2017b). Taken together, HILIC-HRMS is a
promising tool for exposome characterisation.
In the context of this review, using LC-, GC- or IC-HRMS datasets
combined with predictive tools for suspect identiﬁcation in bio-
logical samples is especially advantageous as it enables the eluci-
dation of biotransformation products and pathways, demonstrating
the presence of conserved metabolic enzymes across species
(Bletsou et al., 2015a). Furthermore, animals in the environment are
exposed to a complex mixture of contaminants across their life
cycle. To the authors' knowledge, only one untargeted HRMS
proﬁling method has been applied to occurrence studies in envi-
ronmental biota, tentatively identifying compounds using accurate
mass measurements and isotope ratios of chlorinated or bromi-
nated compounds (Inostroza et al., 2016). Screening methods for
foodstuffs using HRMS have allowed the qualitative determination
of several hundred compounds including pharmaceuticals, pesti-
cides and mycotoxins among others (Dasenaki and Thomaidis,
2015; Perez-Ortega et al., 2016).
5.1. Application of HRMS for environmental metabolomics
In addition to screening for small micro-contaminantmolecules,
screening of biota for thousands of endogenous metabolites can be
achieved simultaneously (i.e. metabolomics) (Gomez-Canela et al.,
2016; Toyota et al., 2016a; Viant and Sommer, 2013). Environmental
metabolomics-based studies have focused on the effect of biotic
and abiotic stressors on both terrestrial and aquatic organisms and
several have used nuclear magnetic resonance spectroscopy (NMR)
and/or GC/LC-MS (Broeckling et al., 2005; Bundy et al., 2004;
Bussell et al., 2008; Grifﬁn et al., 2000; Hines et al., 2007; Skelton
et al., 2014). For example, and in the context of the aquatic envi-
ronment, Toyota and co-workers (Toyota et al., 2016b) recently
used Fourier transform-ion cyclotron resonance direct infusion MS
metabolite proﬁling to better understand the triggers and path-
ways governing the sex of offspring from Daphnia pulex. Jones and
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determine 32 and 51 metabolites, respectively, in order to identify
pyrene exposure in the earthworm Lumbriculus rubellus. Southam
and colleagues (Southam et al., 2014) used direct infusion MS to
determine xenobiotic contamination of roach testes as a result of
wastewater contamination and that the presence of three speciﬁc
compounds (triclosan, chlorophene and chloroxylenol) themselves
had a signiﬁcant contribution to total wastewater induced
biochemical changes.
Despite the breadth of metabolomics-based applications, re-
ports on speciﬁc metabolic changes in aquatic organisms in
response to emerging organic contaminants remain sparse. More-
over, little knowledge exists on the effects of sub-lethal concen-
trations of contaminants on aquatic biota and this is where
environmental metabolomics could prove very useful. This is
important to consider, as exempliﬁed by the study of Alvarez-
Mu~noz et al. (2014) where LC-HRMS was used to examine the po-
tential effect of alcohol polyethoxylates on Solea senegalensis. It was
found that, despite being eliminated during depuration, this sur-
factant induced signiﬁcant metabolite changes upon exposure,
including a ~106-fold increase of in circulating concentrations of
C24 bile acids and C27 bile alcohols. Furthermore, glucocorticoid
and lipid metabolism was disrupted and a 470-fold decrease in
palmitoyl carnitine concentrations were observed (used in fatty
acid transport). We also recently studied sub-lethal concentration
exposures of three pharmaceutical compounds (propranolol, tri-
closan and nimesulide) to G. pulex (Gomez-Canela et al., 2016).
Metabolic changes in a range of amino acids and other metabolites
were identiﬁed and quantiﬁed using SIL-IS. In the real world,
metabolic proﬁling of organisms is likely to be extremely useful for
understanding non-lethal responses to environmental contami-
nants and could be used to elucidate metabolic pathways involved
with such responses. David et al. recently studied the exposome
and metabolome of roach which had been exposed to wastewater
efﬂuent (David et al., 2017). Exposure to efﬂuent for 15 days
resulted in large decreases on prostaglandin in tissue and in plasma
among other perturbations in lipid metabolism. They concluded
that whilst effects could be measured using ‘omics based ap-
proaches, identiﬁcation of the array of contaminants causing such
effects warrants further investigation, potentially by combining the
broadly applicable screening methods highlighted earlier, and even
by using the same analytical technologies (e.g. LC-HRMS).
As a last consideration using HRMS technologies and methods,
linking observed phenotypic changes resulting from pharmaceu-
tical exposure to individual metabolic proﬁles and internalised
drug concentrations would potentially enable a powerful and
mechanistic approach to the assessment of stressors at environ-
mentally relevant concentrations.
6. Pharmaceuticals in the aquatic environment
Pharmaceutical occurrence in abiotic environmental compart-
ments has been the primary focus of monitoring research over the
past two decades (Daughton, 2016). A recent publication has
compiled a database of 123,761 entries for 631 unique pharma-
ceuticals reported across 71 countries (aus der Beek et al., 2016).
Only 16 pharmaceuticals have been found in all UN regions indi-
cating that there is regional variability between occurrence.
Furthermore, there are signiﬁcant regional and national differences
in the prescribing of speciﬁc drugs and brands. This leads to vari-
ation in the source of pharmaceuticals entering the environment
via patient use different from one country to the next, and the
resulting environmental concentration then further depends on the
extent of sewage efﬂuent treatment, and local as well as regionally
variable water availability. However, the wealth of data for abioticcompartments cannot be extended to the biotic compartments. The
number of articles reporting pharmaceutical occurrence in biota is
relatively scarce, with only 43 publications (covering 18 countries,
see SI) in comparison towater/sediment compartments with a total
of 1166 publications (aus der Beek et al., 2016) at the time of writing
this review. Nevertheless, over the last decade the number of re-
ports that have determined the occurrence of pharmaceuticals in
aquatic biota has increased signiﬁcantly. Fish occurrence has been
reported from over a longer period and in marginally greater
numbers (29 publications) than for invertebrates (18 publications).
6.1. Regional occurrence of pharmaceuticals
The spatial distribution of monitoring campaigns also differs
between geopolitical regions (See SI, Figure S1). In North America
and Europe, there is a predominance of occurrence data for ﬁsh and
invertebrates, respectively. East Asia, has had relatively few studies
with the focus on occurrencewithin ﬁsh. The only occurrence study
in South America was in Argentina performed with ﬁsh homoge-
nates (Valdes et al., 2014). Across ﬁsh species, 179 measured
pharmaceutical concentrations have been reported in China (across
5 publications) and 155 measured values were also reported from
locations in the U.S. (across 10 publications). These two countries
account for 68.2% of the positive quantiﬁcations determined in ﬁsh.
Measured concentrations from China covered predominantly
antibiotic classes whereas in the US they covered antidepressants,
antihistamines and calcium channel blockers. The focus of antibi-
otics by China has been reported previously for surface waters (aus
der Beek et al., 2016). Similarly, for the invertebrates, measured
concentrations are predominantly from the US (65 measurements,
across 5 publications) and China (63 measurements, across 2
publications) forming 64% of the measured concentrations.
There are no reported data on pharmaceuticals in biota from
Eurasia (i.e. Russia), Africa, and Australia. These regions also have
very few reported pharmaceutical occurrence data for any
compartment of the aquatic environment (e.g. sediment, water
etc.), thus the potential impacts of these contaminants within these
regions are not well characterised (aus der Beek et al., 2016). This
could be particularly important for developing regions (Tijani et al.,
2016) that have heavily industrialised areas used for pharmaceu-
tical production (Joakim Larsson and Fick, 2009). As an example,
exceedingly high concentrations of pharmaceuticals have been
determined from manufacturing efﬂuents in India (Larsson et al.,
2007), but to the authors’ knowledge no occurrence in biota has
been reported from the region. Occurrence studies from African
countries such as Kenya (Prasse et al., 2010), Nigeria (Olarinmoye
et al., 2016) and South Africa (Matongo et al., 2015) have shown
surface and wastewater pharmaceutical concentrations in the
range generally found in other regions (ng to mg L1). Anti-
retrovirals which are often not studied in other regions accounted
for the largest portion of the total pharmaceutical loads in the
measured surface waters (Prasse et al., 2010). In Australia, phar-
maceuticals such as antibiotics, non-steroidal anti-inﬂammatory
drugs (NSAIDs), antidepressants and lipid regulators have been
detected ranging from ng L1 - mg L1 in surface waters and waste
waters (Scott et al., 2014;Watkinson et al., 2007; Hashim and Khan,
2011). Scott et al. (2014) reported that monitoring of 73 freshwater
sampling sites revealed that carbamazepine and sulfamethoxazole
had hazard quotients >1 indicating the possibility for adverse
effects.
Overall, and given the above examples, international differences
in pharmaceutical occurrence arguably highlights a need to un-
derstand the scale of geopolitical inﬂuence better. Targeted bio-
monitoring programmes for certain classes of compounds will
likely fail to capture the breadth of the issue and until more
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pharmaceutical exposure in non-target biota is limited. It is the
internal exposure which will likely drive impact rather than the
water concentration alone.
6.2. Prevalence of therapeutic classes determined in ﬁsh and
invertebrates
Within the ﬁsh monitoring studies, a total of 490 positive
quantiﬁcations have been reported in the literature, which cover 31
different therapeutic classes of pharmaceuticals. Of these a total of
35% were antibiotics, 18% were antidepressants, 11% were NSAIDs,
10% were antihistamines and the remaining 23% of determinations
were from various pharmaceutical classes (Figure S1). In contrast,
quantiﬁcation of 200 pharmaceuticals have been reported within
the aquatic invertebrate phylum covering 27 classes. A total of 34%
were reported as antibiotics, 22% were antidepressants, 14% were
NSAIDs and the remaining 30% were attributed to various other
classes. In both ﬁsh and invertebrates, the majority of reported
internal concentrations are covered by the antibiotic and antide-
pressant classes. This will be in part due to consumption and usage
patterns where high consumption may lead to higher input in the
environment. For example, antidepressant usage has increased in
Europe by 20% from 2000 to 2010 (Gusm~ao et al., 2013) and use has
approximately increased by two-fold among OECD countries since
2000 (OECD, 2015). Similarly in the US antidepressant usage has
increased signiﬁcantly and these are the third most prescribed drug
across all age groups (Pratt et al., 2005). However, prescription and
over-the-counter medication use can vary by concentration
administered and duration of the course/use/season. Therefore,
prescription rates alone may not explain detection patterns in the
ﬁeld, particularly as dilution is so variable and can be as much as
four orders of magnitude (Keller et al., 2014). This is further high-
lighted with the lipid regulators that have high consumption rates
(OECD, 2015) yet have accounted for 1.5% of the determinations in
ﬁsh and 0.5% of the determinations in invertebrates.
The coverage of pharmaceutical classes reported can also be
explained by several other factors such as seasonal trends, removal
efﬁciency by WWTPs and the bioavailability of the compound. The
absence of certain compounds may also be associated with the
aforementioned Matthew Effect (Daughton, 2014) which limits our
characterisation of the exposome and the potential risk of other
compounds. Consumption data and usage trends could be, in part,
used to direct targeted lists of compounds for biomonitoring as is
the case in water-based monitoring studies. For example, carba-
penems and polymixins have been increasing in their usage (Van
Boeckel et al., 2014), which are classes that are not often moni-
tored for (as with other classes such as anti-retrovirals). In addition,
it is also important to look at the spatial occurrence including
coverage of therapeutic classes together with the regional con-
sumption patterns as it may aid in the identiﬁcation of potential
high-risk areas where there is a lack of measured data. Antibiotic
consumption from 2000 to 2010 has been reported to have
increased by 36%, with 76% of this increase resulting from use in
Brazil, Russia, India, China and South Africa (Van Boeckel et al.,
2014). Thus, surveillance of these regions for these classes of
compounds will be important for identifying any potential unac-
ceptable risk. The occurrence of antibiotics in the environment is
also a human health hazard due to the rise of antimicrobial resis-
tance (Hirsch et al., 1999). The occurrence of trace pharmaceuticals
in animals (and other environmental compartments) could drive
selection pressures for mobile genetic elements associated with
drug-resistance (Wellington et al., 2013). Thus, measuring anti-
biotic occurrence in biota could also aid the surveillance of anti-
microbial resistance (Le Page et al., 2017).7. Occurrence of pharmaceuticals in ﬁsh species
At present, a total of 61 different species of ﬁsh have been used
to study the occurrence of pharmaceuticals across both freshwater
and marine environments. Comparison of the reported ﬁsh tissue
and plasma/bile concentrations showed quite clearly that ﬁsh tis-
sue concentrations had much greater coverage. This is perhaps
surprising given that plasma measurements can be useful for
determining potential effects when related to the human thera-
peutic plasma concentrations (Cmax) by means of the Fish Plasma
Model (Huggett et al., 2003). However, the authors note that there
can be signiﬁcant difﬁculty in obtaining plasma samples from ﬁsh
in the ﬁeld where whole-body and tissues samples allow much
greater ﬂexibility, especially for animals that are small in size
(particularly for haemolymph sampling in invertebrates). The use
of the Fish Plasma Model has been investigated for more than 10
years (Rand-Weaver et al., 2013) and recently direct evidence of
cause and effect has been established (Margiotta-Casaluci et al,
2014, 2016). Thus, the use of this model would complement bio-
monitoring studies as it would allow the derivation of the effect
ratio (ER) and hence the potential risk to ﬁsh populations. The
model was ﬁeld tested using sewage efﬂuents by Brown et al.
(2007) and Fick et al. (2010) where several pharmaceuticals ach-
ieved a comparable plasma concentration to human therapeutic
levels, with ERs ranging from <1 to >1000.
The determination of internal concentrations in ﬁsh species has
ranged from 0.02 to 2390 ng g1 across tissues and from 0.055 to
567 ngmL1 in ﬁsh plasma or bile measurements (Fig. 3 and
Table S2). The highest concentrations reported in ﬁsh tissue stem
from the macrolide/quinolone antibiotics and in ﬁsh plasma/bile
measurements. Erythromycin was measured at 545 ngmL1 and
lincomycin was measured at 567 ngmL1 in plasma. Sulfonamides
and quinolones have been quantiﬁed in plasma, however, remained
144 ngmL1 (sulfamethazine). NSAIDs and calcium channel
blockers are the next highest determined concentrations in ﬁsh bile
and plasma measurements with medians of 16.5 ngmL1 and
15.74 ngmL1, respectively. Antihistamines and other pharmaceu-
tical classes (including tricyclic antidepressants (TCA), lipid regu-
lators, selective serotonin reuptake inhibitors (SSRI) and
antipruritics (among others)) have been reported with median
concentrations 0.97 and 1 ngmL1, respectively. The relatively
lower concentration of these compounds could be explained by
tissue speciﬁc accumulation (i.e. tissue partitioning> blood parti-
tioning), or that the compounds show relatively little accumulation
overall. For example, the antihistamine tissue concentrations had a
median of 0.91 ng g1 which corresponds well with the median
values determined for the plasma/bile median, suggesting that the
antihistamine compounds that have been measured potentially
have low accumulation in ﬁsh. An important metric used regularly
in pharmacology that could inform the potential for tissue distri-
bution of pharmaceuticals in non-target biota is volume of distri-
bution (VD), where databases are available with this information
summarised (Berninger et al., 2016).
7.1. Antidepressants and their biotransformation products
determined in ﬁsh
Antidepressant measurements within ﬁsh tissues ranged up to
600 ng g1, with the largest concentration measured within the
SSRI metabolites (norsertraline) (Du et al., 2012). The TCAs have
been reported at lower concentrations in comparison to other an-
tidepressant classes. The 75th percentile of occurrence data was
3.51 ng g1, ~5e9-fold lower than the 75th percentile of the
remaining classes. Whilst not strictly a TCA, most frequently re-
ported tricyclic pharmaceutical was carbamazepine, which has also
Fig. 3. Reported concentrations of different pharmaceutical classes determined in ﬁsh (a) tissues and (b) plasma or bile. The Other category denotes various pharmaceutical classes
that were reported infrequently from the literature. Boxes represent the 25th, median and 75th percentile, whiskers represent 10 and 90th percentile and dots indicate outliers.
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species (Miller et al, 2016, 2017; Meredith-Williams et al., 2012;
Boillot et al., 2015; Garcia et al., 2012). Other antidepressants
including the serotoninenorepinephrine reuptake inhibitors
(SNRI), norepinephrineedopamine reuptake inhibitor (NDRI) and
benzodiazepines were reported to occur at similar concentration
ranges to the SSRI class. Interestingly, within the SSRI class of
pharmaceuticals, the spread of the metabolite data showed larger
summary statistics (mean, median, min/max and interquartile
ranges) indicating that SSRI metabolites were often present at
higher concentrations in comparison to the precursor compound.
This suggests that SSRI metabolites may bemore accumulative than
their precursor, or that metabolism is rapid. This higher accumu-
lation has been observed from individual studies where Du et al.
(2012) measured much higher relative concentrations of the SSRI
metabolite norsertraline in both liver and muscle tissue. This is also
consistent with toxicokinetic studies where some other classes of
pharmaceutical metabolites have accumulated more than the
parent compounds (e.g. benzodiazepines) (Miller et al., 2017; Lahti
et al., 2011). A t-test assuming unequal variances showed that the
there was no statistically signiﬁcant difference between the re-
ported concentrations of either group (p-value 0.67, alpha¼ 0.05).
Nonetheless, if some biotransformed products do have higher
accumulation than precursor compounds, then there is a potential
for greater risk in the environment. Prodrugs are an important
consideration here, as the biotransformation product is the phar-
maceutically active compound. However, as biotransformation is
often not considered during monitoring campaigns, and only in
part of the European regulatory environmental risk assessment
since the focus is on the product, there remains a potential gap that
should be addressed in future works (Boxall et al., 2012).
7.2. Antibiotics and other determined therapeutic classes in ﬁsh
Among antibiotic measurements the highest detectedconcentrations were 2390 ng g1 for erythromycin (Zhao et al.,
2015) and 1600 ng g1 for ormetoprim (Meador et al., 2016).
Whilst these compounds have been reported to reach these high
concentrations, most often the concentrations remain relatively
low. Median values for macrolides, quinolones and sulphonamides
were 3.60, 5.23 and 7.35 ng g1, respectively. The only other class of
antibiotics to be quantiﬁed in ﬁsh were the tetracycline com-
pounds, oxytetracycline (50 ng g1) and chlortetracycline
(160e590 ng g1). Beta-lactam antibiotics have not been deter-
mined in ﬁsh (or invertebrates) although measured concentrations
have been determined in surface waters ranging from low ng L1 to
mid ng L1 concentrations (aus der Beek et al., 2016). The remaining
classes of compounds including the antihistamines, NSAIDs, cal-
cium channel blockers and beta-blockers showed relatively low
concentration ranges when compared with the antidepressants or
antibiotics, with the 75th percentile ranging from 1.71 ng g1 (cal-
cium channel blockers) to 11.51 ng g1 (beta-blockers).
The majority of reported concentrations in each of these ther-
apeutic classes is largely representative of only a single compound
such as diclofenac (NSAIDs), diphenhydramine (antihistamines),
propranolol (beta-blockers) and diltiazem (calcium channel
blockers). These are often the most common compounds that are
targeted and demonstrate the potential bias associated with the
Matthew Effect. The data for these single compounds show that
measured concentrations can vary quite considerably for the same
compound (Figure S2). The scatter in the measured concentrations
is likely to arise from the temporal and spatial ﬂuctuations of sur-
face water/sediment pharmaceutical concentrations in addition to
other factors (pH, bioavailability, temperature etc.).
Diclofenac, in particular, was measured at concentrations
reaching up to 148 ngmL1 in plasma and 13.8 ng g1 in ﬁsh
muscle, from ﬁeld samples. The concentration in the muscle tissue
is approximately 5-fold lower than the concentration in the muscle
associated with the No Observed Effect Concentration (NOEC) of
1 mg L1 proposed by Schwaiger et al. in water (Schwaiger et al.,
Fig. 4. Reported concentrations of different pharmaceutical classes determined across
various invertebrate species. The Other category denotes various pharmaceutical
classes that were reported infrequently from the literature. Boxes represent the 25th,
median and 75th percentile, whiskers represent 10 and 90th percentile and dots
indicate outliers.
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(PNEC) has been proposed at 0.1 mg L1 and measured environ-
mental concentrations have exceeded this value in 12 countries
(aus der Beek et al., 2016). Measured plasma concentrations of
diclofenac exposed at 1.6 mg L1 reached ~9 ngmL1 and exposure
at 11.5 mg L1 reached ~60 ngmL1 (Cuklev et al., 2011). In another
study, plasma concentrations of diclofenac reached over
113.1 ngmL1 andwas associated with an exposure level of 5 mg L1
over a 21-day period (Bickley et al., 2017). These reports indicate
that concentrations of diclofenac in ﬁsh plasma from the ﬁeld have
exceeded laboratory determined plasma concentrations associated
with exposure levels much greater than some proposed PNEC or
NOEC. However, there remains an unresolved debate regarding the
replicability of the reported ecotoxicology studies; some suggest
the population endpoint relevance could be as much as 320 mg L1
in the water (Memmert et al., 2013). The ongoing debate in the
literature is critical to resolve the balance between protecting the
environment from population adverse effects, and weighed against
this the value of human medicines (Acu~na et al., 2015).
The ‘other’ grouping of pharmaceuticals was combined
measured data that comprised another 17 various pharmaceutical
classes but had only been reported with a total of 7 measured
values. Lipid regulators are one such class and have had only 7
reported occurrences across ﬁsh despite them being some of the
most prescribed compounds globally (OECD, 2015; Lindsley, 2012).
In liver tissue, gemﬁbrozil has been measured reaching up to
90 ng g1 (Ramirez et al., 2009). The highest measured plasma
concentration was 109 ngmL1 (Brown et al., 2007). Plasma con-
centrations of 170± 20 ngmL1 have been shown to be associated
with a 50% decrease in goldﬁsh testosterone levels, suggesting the
possibility of endocrine disruption (Mimeault et al., 2005). How-
ever, the human therapeutic concentration is approximately
2500 ngmL1 without changes in testosterone (Schulz et al., 2012).
If gemﬁbrozil does elicit endocrine disruption in ﬁsh, themaximum
measured environmental concentration (109 ngmL1) leads to the
possibility of adverse effects in the environment if ﬁsh are acutely
susceptible to testosterone modulation. Currently, effects related to
measured internal concentrations are limited. Effect-based studies
have generally linked exposure concentrations to observed effects.
Thus, the cause and effect relationship is limited as toxicological
endpoints are inferred from a dosed concentration in water rather
than using measured internal concentrations. The use of internal
concentrations are critical as they can directly link the cause and
effect leading to improved risk assessment (Rand-Weaver et al.,
2013), yet it was only a few years ago that this was ﬁrst demon-
strated in ﬁsh (Fick et al., 2010).
8. Occurrence of pharmaceuticals in invertebrates
The most frequently reported concentrations in invertebrates
belong to antibiotics and antidepressant therapeutic classes, with
concentrations determined ranged from 0.20 to 320 ng g1 for the
antidepressants, 0.10e430 ng g1 for antibiotics, 2.10e430 ng g1
for NSAIDs, 0.30e12.10 ng g1 for antihistamines and
0.10e210 ng g1 for the other therapeutic classes (Fig. 4). Within
the antidepressant class, the SSRIs showed relatively higher inter-
nal concentrations when compared to the TCAs and the other an-
tidepressant classes including benzodiazepines and SNRIs. The
higher occurrence of the SSRIs also compares with the ﬁsh occur-
rence data where SSRIs showed increased concentrations relative
to the TCA class. Therefore, the data suggests that the SSRI class of
antidepressants may have a higher risk potential than other anti-
depressants. This would reﬂect current trends in effects studies
which have focussed on SSRI antidepressants (Silva et al., 2015).
However, the most frequently reported SSRIs from biomonitoringstudies are ﬂuoxetine and sertraline that may lead to possibility of
biasing occurrence data. Further, both of these drugs have complex
pharmacology where the primary metabolites are the pharmaco-
logically relevant compound, and transformation in the environ-
ment will play an important role in their risk proﬁle. Whilst the
data available suggests that individual compounds such as ﬂuoxe-
tine might have increased risk in the environment (Fong and Ford,
2014; Brooks, 2014), other studies have demonstrated responses
only at non-environmentally relevant concentrations engineered to
generate internal concentrations in the human therapeutic range
(Margiotta-Casaluci et al., 2014).8.1. Antibiotics in invertebrates
The maximum concentration determined among the antibiotic
classes was from the compound sulfamethazine which reached up
to 430 ng g1 (Dodder et al., 2014). However, in general, the sul-
fonamides showed low level occurrence with all remaining
measured concentrations <15.3 ng g1. Toxicity of selected sulfon-
amide antibiotics (sulfamethazine included) have been reported in
crustaceans with EC50 levels for often in the mg L1 range (García-
Galan et al., 2009; Białk-Bielinska et al., 2011; De Liguoro et al.,
2009). Furthermore, hazard quotients have been estimated for
ﬁsh and invertebrates and demonstrate that sulfonamides have low
risk in the aquatic environment (with the exception to algae)
(García-Galan et al., 2009). The macrolides and quinolones show
maximum measured concentrations of 132 ng g1 and 170 ng g1,
respectively. However, in general these classes of compounds
showed low occurrence in invertebrates with median concentra-
tions of 2.32 ng g1 and 10.60 ng g1. Available effect data for the
quinolones is limited, but a study involving the toxicity of cipro-
ﬂoxacin to ﬁsh and invertebrates showed toxicity thresholds of mg
L1 concentrations on a range of endpoints (mortality, growth,
reproduction) (Martins et al., 2012). The paper showed that hazard
quotients were <1 indicating little or no risk. (Martins et al., 2012;
Halling-Sørensen et al., 2000). However, it should be noted that for
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(including luminescence inhibition and growth) determined across
the therapeutic classes are usually algae and cyanobacteria (Yang
et al., 2011; Ji et al., 2012; Baumann et al., 2015), thus these often
represent the worst-case scenario (Le Page et al., 2017).8.2. NSAIDs, antihistamines and biotransformation products
determined in invertebrates
The remaining most frequently detected compounds belonged
to the class of NSAIDs and antihistamines. The antihistamine groupFig. 5. Reported accumulation of pharmaceuticals in ﬁsh and invertebrates determined in t
pharmaceutical accumulation in ﬁsh and invertebrates (invert) (b) comparison of reported ph
the ﬁeld. BCF/BAF axis label denotes that the value is either a BCF or a BAF. Boxes represent th
indicate outliers.consisted of only measurements of diphenhydramine which
showed median concentrations of 3.38 ng g1, with the largest
measured internal concentration reaching 12.10 ng g1. As with
occurrence in ﬁsh, this suggests that the compound diphenhydra-
mine has a relatively low accumulation potential (albeit several
higher measurements were reported in ﬁsh, Table S2/S3). Alter-
natively, the low measured internal concentrations may be a result
of a low occurrence in surface waters. NSAID residues in in-
vertebrates were relatively higher (median¼ 20.50 ng g1) than
compared with other classes of pharmaceuticals (Fig. 5). The most
frequent NSAID determined was diclofenac with a median ofhe ﬁeld (in situ) and in the laboratory (in vivo). (a) comparison of reported whole body
armaceutical accumulation in different ﬁsh tissues determined in the laboratory and in
e 25th, median and 75th percentile, whiskers represent 10 and 90th percentile and dots
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celecoxib with a median of 24 ng g1. In general, while they show
relatively higher measured internal concentrations, the risks
NSAIDs pose to invertebrates have been reported to be low
(Constantine and Huggett, 2010; Gonzalez-Ortegon et al., 2013;
Heckmann et al., 2007).
Biotransformation products have been determined relatively
infrequently across invertebrates with only 12 reported concen-
trations (See SI, Table S3), half of which were associated with
norsertraline. Such infrequency in occurrence reports can be
explained in part by the low number of analytical methods that
have targeted biotransformation products. Comparison of
measured internal concentrations of sertraline and norsertraline
showed that they were quantiﬁed in the same ranges
(0.4e370 ng g1 and 9.8e88 ng g1, respectively). The remaining
metabolites quantiﬁed included carbamazepine-10,11-epoxide, 2-
hydroxycarbamazepine, 10-hydroxyamitriptyline, norﬂuoxetine
and norvenlafaxine, all of which were 4.55 ng g1, similar to
measured concentrations of their precursors. Biotransformation
product occurrence data are limited for surface waters and biota.
However, untargeted analytical methods that can be used to proﬁle
extensive xenometabolic pathways of pharmaceuticals in biota are
now emerging (Bletsou et al., 2015b; R€osch et al., 2016). These
methods will thus be valuable for determining which biotransfor-
mation products to target going forward.
9. Field versus laboratory accumulation of pharmaceuticals
Whole body accumulation is expressed as either (a) bio-
concentration factors (BCF) representing the compound accumula-
tion solely from the water, or (b) bioaccumulation factors (BAF) that
represent accumulation from both the water and diet. Field based
assessment of accumulation is reported as BAF. A further term used
in deﬁning accumulation is a biomagniﬁcation factor (BMF), which
describes the propensity of a compound to biomagnify up the food
chain. Larger values of BCF, BAF or BMF indicate more pronounced
accumulation where regulatory thresholds for compounds to be
considered bioaccumulative have been deﬁned as 1000 L kg1
(depending on the regulatory body). It must be noted that BCF in the
academic literature often is calculated as the ratio between the
instantaneous measured internal and external concentrations i.e. a
BCF of 10would suggest that the internal concentrationwas found to
be ten times that of the water. In a regulatory context, the BCF is a
kinetic measure established via a standardised test protocol (e.g.
OECD 305) where it is the ratio between the rate of uptake and the
rate of depuration. Occurrence data can often indicate compounds
thatmay show a potential to accumulate in organisms. However, it is
laboratory in vivo exposures studies that can elucidate toxicokinetic/
toxicodynamic (TKTD) properties of these compounds, identify
hazards associated with exposure, and help prioritise compounds of
concern for targeted analytical approaches in environmental moni-
toring campaigns. The earliest published laboratory study to deter-
mine a pharmaceutical bioconcentration factor that we could ﬁnd
was by Hou et al. (2003) in 2003, where the authors exposed stur-
geon to sulfamethazine. Currently, 57 publications have dealt with
the accumulation of pharmaceuticals across ﬁsh and invertebrates,
with approximately >640 BCF/BAFs covering 90 unique pharma-
ceuticals estimated (ﬁeld BAFs, n¼ 418). The most frequently re-
ported BCF or BAF data included six pharmaceuticals in the order of:
carbamazepine> erythromycin> diclofenac> roxi-
thromycin> ibuprofen> propranolol. The compounds carbamaze-
pine, propranolol, ibuprofen and diclofenac have also been reported
to be the most the frequently cited compounds (among 8 others)
from prioritisation reviews of emerging environmental contami-
nants (Donnachie et al., 2016).Current evidence does not indicate that pharmaceuticals bio-
magnify (Du et al., 2014; Lagesson et al., 2016; Xie et al., 2017). In
contrast, studies focussed on trophic transfer of pharmaceuticals
have observed that internal concentrations are often larger in in-
vertebrates when compared to ﬁsh. This suggests that dietary
accumulation of some pharmaceuticals is likely to play a minor role
in accumulation (Du et al., 2014; Lagesson et al., 2016), at least in
ﬁsh. Comparison of whole body accumulation data in invertebrates
showed that ﬁeld determined values could be perceived as higher
when compared to estimates from laboratory studies (Fig. 5(a)). A
single factor ANOVA showed that there was no statistically signif-
icant difference between the ﬁeld and laboratory values (p-
value¼ 0.536). No statistically signiﬁcant difference between the
sensitivities to accumulation in invertebrates and ﬁsh were
observed within the laboratory data (one tailed t-test assuming
unequal variance, p-value¼ 0.155). However, it should be noted
that the whole-body accumulation data are not homogenous, so
differences in accumulation between the organisms for the same
compounds might not be apparent. Furthermore, ﬁeld BAFs for ﬁsh
were limited with only one study published that determined a
whole-body BAF (Valdes et al., 2016).
The largest laboratory BCF reported was for the SSRI ﬂuoxetine
that reached 185,900 L kg1 in the freshwater arthropod, Gamma-
rus pulex (Meredith-Williams et al., 2012). This compound has been
the subject of many publications related to its impact in the envi-
ronment for all persistence, bioaccumulation and toxicity (PBT)
criteria (Brooks, 2014; Brooks et al., 2003). However, several other
accumulation estimates were shown to be> 62-fold lower
(Table S3), albeit for different animals under different experimental
conditions. The largest measured BAF was for the compound hy-
droxyzine (96,000) in a freshwater snail (Planorbidae sp.) (Lagesson
et al., 2016). However, this compound was shown to have a large
accumulation range across different species (ﬁsh and invertebrates)
with the lowest estimated BAFmuscle of 1050 for Perca ﬂuvitalis,
indicating that sensitivity to accumulation can vary across species
by ~100-fold. Hydroxyzine was also shown to have an in vivo BCF of
2000 in Zygoptera larvae that was approximately 7-fold lower than
the in situ BAF determined for the same species (14,340) (Lagesson
et al., 2016; Jonsson et al., 2014). Taken together, this suggests that
this compound may be bioaccumulative, particularly to in-
vertebrates. However, exceptionally high values of accumulation
should be considered with caution, if correct we should expect to
see this widely repeated in analysis of environmental samples in
future.
The difference between laboratory and ﬁeld estimations of
accumulation could be attributed to dietary assimilation and other
environmental/ecological factors such as feeding strategy, habitat
choice, water chemistry and bioavailability (Vignati et al., 2007;
Hird et al., 2016). As in vivo tests do not often include dietary
exposure, it has been suggested that this may underestimate the
accumulative potential of a compound (Lagesson et al., 2016).
However, while dietary exposure can affect accumulation, studies
have demonstrated that accumulation of contaminants through the
diet generally show little inﬂuence on the compounds that have
been tested andmay only bemore relevant for higher trophic levels
(Lagesson et al., 2016; Ashauer et al., 2010; Du et al., 2015). Differ-
ences in accumulation have also been shown where multiple spe-
cies have been analysed from the same ﬁeld site (Li et al., 2012; Xie
et al., 2015). The differences in accumulation here have been pro-
posed to be inﬂuenced by a number of factors, including lipid
content of the organism, body size, life stage and respiration
strategy (Meredith-Williams et al., 2012; Arnot and Gobas, 2006;
Ruhí et al., 2016; Rubach et al., 2010).
With this variety of different factors affecting accumulation,
comparisons of BAFs/BCFs between publications may hold little to
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experimental and analytical conditions are replicated (Xie et al.,
2015). Additional reasons for the observed disparity between
ﬁeld and lab-based bioaccumulation data is due to the ﬂuctuations
in both spatial and temporal concentrations of pharmaceuticals in
the ﬁeld. This is the inherent uncontrolled variance that can be
associated with in situ measurements (Xie et al., 2015; Scott et al.,
2016; Cantwell et al., 2017). Therefore, ﬁeld-derived BAF estima-
tions using surface water concentrations may lead to over/un-
derestimates. Additionally, it is difﬁcult to characterise the
exposure that animals have received, since many species are
migratory (due to factors such predator avoidance, drift, seeking
food or a mate, and seasonal environmental changes). However,
there is still value in spot samples of measured internal concen-
trations in the ﬁeld because they can give an integrated value of
temporal exposure that include toxicokinetic/toxicodynamic pro-
cesses. The ﬂuctuation of the environmental exposure probably
more closely relates to the changes in pharmacodynamics within
man. It is the area under the curve (AUC) in the treatment scenario
that is most important to the pharmacologist and the half-life of a
drug within the patient is of critical value, but few ecotoxicology
studies have attempted to address this. One exception looking at
the effects of glucocorticoids linked the AUC to internal exposure
resultant from a ﬂuctuating water exposure concentration and used
this to develop a quantitative adverse outcome pathway for this
class (Margiotta-Casaluci et al., 2016). This concept could be the
basis of future laboratory studies, in order to more realistically
mimic the environment accounting for exposure ﬂuctuations as
long as dosing is measured appropriately.
9.1. Tissue speciﬁc accumulation of pharmaceuticals
The disparity between in-ﬁeld and laboratory studies was also
observed upon comparison of tissue accumulation factors across
ﬁsh (Fig. 5(b)). For all ﬁsh tissue measurements, the laboratory
estimations were generally lower than the in-ﬁeld data. The me-
dians of each tissue subgroup ranged from 10 to 494-fold higher for
the in-ﬁeld accumulation data when compared to laboratory data.
The largest difference in medians belonged to estimations in bile.
Bioaccumulation was observed to be relatively higher in liver, bile
and brain tissue for both laboratory and in-ﬁeld measurements.
Greater partitioning of pharmaceuticals into these two tissues
types might be expected since (a) the liver serves as the primary
site of detoxiﬁcation processes, and (b) there is selected transport of
speciﬁc pharmaceuticals that have conserved molecular targets in
the brain (e.g. antidepressants). It has been reported that antide-
pressants such as citalopram, sertraline and venlafaxine were
detected at higher concentrations in the brains of ﬁsh when
compared to other tissues (Grabicova et al., 2014; Lajeunesse et al.,
2011).
Bile measurements had the largest median across all in-ﬁeld
subgroups. It may be expected that bile would display greater
accumulation factors in comparison to other tissues, as xenobiotic
detoxiﬁcation often involves the transport of contaminants in bile
into the bile canaliculi for either reabsorption or excretion. Many of
the in-ﬁeld bile accumulation estimates were derived from a single
study focussing on antibiotic classes (Zhao et al., 2015). Biliary
transport and excretion are an important elimination route for
these types of pharmaceuticals (Karachalios and Charalabopoulos,
2002). It is interesting to consider that here bile serves as an
elimination route containing excretory products and so demon-
strates that ﬁsh can eliminate pharmaceuticals from the body. The
relevance of bile measurement in occurrence and accumulation
data is whether these pharmaceutical excretory products remain
biologically active. In contrast to the in-ﬁeld data, bilemeasurements represented the lowest median accumulation fac-
tors across all laboratory exposure tissue subgroups. Muscle tissue
accumulation for the in-ﬁeld data was the group that showed the
second lowest median of 161.5 (lowest median was in plasma). In
laboratory studies, muscle accumulation was also low with a me-
dian value of 2.88. The data indicates that distribution and accu-
mulation of pharmaceuticals into muscle tissues is relatively low.
This has been demonstrated in tissue speciﬁc accumulation studies
(Zhao et al., 2015; Grabicova et al., 2014; Lajeunesse et al., 2011).
However, pharmaceuticals have a relatively limited focus in the
literature in this respect. This is of particular importance, as sub-
stances that have high accumulation in a speciﬁc tissue may still
lead to deleterious effects and risk assessments based on whole-
body accumulation factors might not describe this risk accurately
as a result. Furthermore, biomonitoring studies that determine the
internal pharmaceutical concentrations from muscle tissue may
not give a reliable estimate of the extent of occurrence. As tissue
distribution for pharmaceuticals in this compartment is likely to be
low, potentially reﬂecting the blood ﬂows and distribution
depending on the compound, species and life stage.
An ANOVA analysis for ﬁsh tissue accumulation between labo-
ratory and in-ﬁeld data indicated that there was a statistical sig-
niﬁcance between the measured data (p-value¼ 2.3946). A post-
hoc analysis was performed using Tukey's test to identify which
tissue subgroups (i.e. liver, gills, muscle etc.) led to the signiﬁcant
differences (See SI, Figure S3 and Table S3). Based on pairwise
groupings, only two tissue-speciﬁc accumulation data groups were
signiﬁcantly different; the liver and bile. The signiﬁcance may
indicate that uptake in the ﬁeld is more pronounced for these tis-
sues when compared with laboratory-based testing. This disparity,
among other factors mentioned above (such as environmental in-
ﬂuences), could also arise due to the exposure in the ﬁeld to large
mixtures of pollutants rather than pharmaceuticals alone. Thus,
exposure to complex mixtures may manifest through increased
detoxiﬁcation processes involving bile and the liver, leading to
higher accumulation in these tissues. However, without high fre-
quency sampling of surface waters, whether this signiﬁcance is
related to lower quality BAF estimates resulting from temporal
ﬂuctuations in contaminant surface water concentrations remains
unclear.
10. Recommendations for future research
This review has summarised the occurrence of pharmaceuticals
in biota to 2016, as well as emerging ways to potentially charac-
terise the pharmaceutical component of the exposome more reli-
ably. Several limitations still exist as identiﬁed in 2011, such as (a)
limited data on tissue concentrations exist (b) ecotoxicity studies
rarely report tissue concentrations and (c) limited breadth of target
analytes (Beyer and Meador, 2011) indicating that progress within
the ﬁeld remains relatively slow. To further advance knowledge
within environmental toxicology these gaps need to be urgently
addressed and a number of other key issues have been identiﬁed
since then. We propose the following set of recommendations
which may begin to address existing and emergent gaps in
knowledge, potentially towards improving pharmaceutical envi-
ronmental risk assessments.
1) Standardise analytical methods, where possible, and adhere
more strictly to method validation guidelines to ensure robust
quantiﬁcation. Harmonisation of the available guidelines for
method validation that exist (Magnusson and. €Ornemark, 2014;
(ICH), 1994; Food and D, 2015; Committee, 1998; Thompson
et al., 2002; Pharmacopoeia and U. and U., 2003) would enable
movement away from method performance towards method
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been regulated for several years and conform to stringent vali-
dation criteria which could be adapted to environmental toxi-
cology research. More speciﬁcally, guidelines for method
validation using HRMS are also lacking. The importance of
reliable and robust analytical methods within the ﬁeld, is the
foundation of which ecotoxicological studies should be based
on.
2) Measurement of internal concentrations (including biotrans-
formation products) in biota will enable more reliable risk
assessment for pharmaceuticals in the environment than those
based solely on concentrations in water (i.e. PEC/PNEC) and
hence aid prioritisation of hazardous compounds. Internal
concentrations are the initiating event for any potential phar-
macological or toxicological effects and will be key to under-
standing risk.With respect to this, it is also advisable that effect-
based studies should also quantify compound concentrations
associated with the observed effects in biota. This will enable
the establishment of the cause-effect relationship and threshold
associated with the onset of the effect, and hence avoiding the
vagaries of extrapolation of exposure concentrations to
observed effects
3) Tissue speciﬁc distribution should also be determined, where
possible, as single compartment measurements may not detect
or artiﬁcially underestimate concentrations (via whole-body
measurements). Preferential distribution of a compound into a
speciﬁc tissue may cause localised effects, and so single
compartment measurements may fail to characterise the po-
tential risk to an organism. Advancements in mass spectro-
metric methods for imaging could be pursued to identify
localisation of pharmaceuticals within an organism (Hsieh et al.,
2007; Solon et al., 2010).
4) Focus more on untargeted, hyphenated HRMS analytical
methods for screening purposes. The use of HRMS would also
avoid biased pre-selection of contaminants (which may under-
represent the true extent of environmental risk). Additionally,
proﬁling in this way will also enable the elucidation of
biotransformation pathways to inform toxicokinetic and effect-
based assessments. The potential to simultaneously study
complex mixtures, including metabolites and transformation
products becomes possible towards better characterisation of
the exposome and metabolome, for example. Of course, expo-
sure at environmentally relevant concentrations are more likely
to reﬂect the wild situations. Where technically possible these
low concentrations would help avoid situations where con-
centration dependant uptake is an issue.
5) Develop and validate new in silico approaches for mining of
so called ‘big data’ generated from untargeted methods should
be urgently prioritised. With the previous recommendation of
using HRMS, it is necessary to have tools that can expedite
interpretation of these increasingly large and complex datasets.
As ‘predictive ecotoxicology’ is becoming more well established,
we must ensure that models are reliable and robust for these
purposes.
6) Improve reporting. The reproducibility and replicability of
studies could be improved by better standardised reporting of
methods and data. For ionised compounds, the pH of the
exposure media is critically important and, whilst often re-
ported, it is not universally so. Similarly, concentration data
from biomonitoring studies vary widely in presentation. For
example, frequency is inconsistently given among reports. In
addition, more of the exposure conditions should be reported
(i.e. meta-data) to make the derived data of wider applicability
for the future development of in silicomodels. It would also helpavoid typographical errors if all publications used the same units
of measurement when reporting concentrations in water.
Ultimately, reliable and robust analytical methods underpin
understanding of the occurrence of pharmaceuticals in biota and
the risks they may pose. Analytical capabilities are ever-increasing
for broad-scope, targeted and untargeted biomonitoring which can
be used in an interdisciplinary approach to characterise the phar-
maceutical component of the exposome. Whilst the ﬁeld of envi-
ronmental toxicology has already seen a wealth of research in
emerging contaminants, we remain unclear on the scale of phar-
maceutical contamination and their potential combined effects on
biota.
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